Анализ ценовых характеристик монокомпонентных пероральных сахароснижающих средств на фармацевтическом рынке Республики Крым

Abstract

Introduction. Currently, diabetes mellitus is one of the commonest socially important diseases in the Republic of Crimea. In 2019 the incidence of diabetes mellitus in the population of the Republic amounted to 354.6 per 100 000 people, having outnumbered the figures of the previous year by more than 50%. Aim. Price analysis of monocomponent oral hypoglycemic drug (OHGD) range offered on the pharmaceutical market of the Republic of Crimea. Materials and methods. The object of research conducted during the first half of 2021 was the range of monocomponent OHGDs offered in the pharmaceutical organizations on the territory of the Republic of Crimea. The source of information on the price of single medicinal products (MPs) administered for type 2 diabetes mellitus was the average retail prices of regional specialized pharmacy organizations – the Limited Liability Companies “Apteka Martana” and “Semeinaya Apteka.” Results. The OHGDs market of the Republic of Crimea is represented by 55 trade names of monocomponent MPs, among which the drugs of biguanide group (16 trade names), sulphonylurea derivatives (29 trade names), dipeptidyl peptidase-4 inhibitors (8 trade names) predominate. The distribution of drugs by country of origin revealed the prevalence of medicinal products of domestic manufacture (73.3%). The price segmentation of monocomponent OHGDs demonstrated the prevalence of MPs of the low price segment. Conclusion. The study of monocomponent OHGD range in the pharmacies of the Republic of Crimea enabled to ascertain the high indices of import substitution and the considerable proportion of monocomponent OHDs of the low price segment, which makes the studied group accessible for the patients with type 2 diabetes mellitus.